US 12,077,602 B2 · IgG epitope and applications thereof as a drug target

Abstract

IgG epitope and applications thereof as a target are provided. The IgG epitope is the CH1 domain of non-B cell-derived IgG, and there is N-glycosylated sialic acid modification at the Asn162 site of the domain. The realization of its antigen functions must depend on the sialylation of the site. The present invention further discloses the applications of the IgG epitope as a drug target in preparing drugs for diagnosis and/or treatment of epithelial tumors. In addition, our studies showed that this antigen depends on the sialylation of Asn162 site as a drug target, and the sialylation of this site must depend on sialyltransferase ST3GAL4, indicating that the enzyme can be used as a drug target for preparing tumor therapeutic drugs. Further, integrin β4 is co-expressed and co-localized with IgG containing the epitope. IgG can be used as a marker for preparing drugs for the auxiliary detection of epithelial tumors.

Claims4

Dependent claims

A method of diagnosis of an epithelial tumor expressing a sialylated RP215-IgG, comprising:

obtaining an epithelial tumor tissue sample from a subject;
determining the presence of a sialylated RP215-IgG expression pattern in the epithelial tumor tissue using a monoclonal antibody, wherein the monoclonal antibody comprises epitope-specific site binding to a CH1 domain of non-B cell derived IgG comprising the amino acid sequence of SEQ ID NO:
1 with an N-glycosylated sialic acid modification at an Asn162 site of the CH1 domain and is a RP215 monoclonal antibody;
and
predicting metastasis and poor prognosis of the epithelial tumor by detection of the sialylated RP215-IgG in the epithelial tumor tissue sample.

2 more elements

Dependencies are inferred from the claim text.

IgG epitope and applications thereof as a drug target

Life of this patent

IgG epitope and applications thereof as a drug target

Life of this patent

Abstract

Claims4